^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VTX-0811

    i
    Other names: VTX-0811, 617 anti-PSGL-1 antibody
    Associations

    News

    Trials
    Company:
    3SBio, Verseau Therap
    Drug class:
    PSGL-1 antagonist
    Associations

    News

    Trials
    almost4years
    VTX-0811, a first-in-class PSGL-1 blocking monoclonal antibody, repolarizes tumor associated macrophages and induces inflammation in the tumor microenvironment, leading to suppression of tumor growth in pre-clinical studies (AACR 2022)
    VTX-0811 does not induce activation of unstimulated PBMC or unstimulated blood-derived neutrophil or T cell cultures. These data provide biological and mechanistic support for advancing this program into the clinic with a first in human trial planned for early 2022.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    VTX-0811